NLK and hepatocellular carcinoma: Various studies have concluded that miR-101 suppress HCC by targeting an oncogene known as enhancer of zeste homolog 2 (EZH2), myeloid cell leukemia sequence 1 (Mcl-1) and Nemo-like kinase (NLK) [17.18,19].